Sinopharm/Oramed Deal Sets Up Huge China Market For Oral Insulin
This article was originally published in PharmAsia News
Chinese pharmaceutical giant Sinopharm’s subsidiary has finalized a licensing agreement with Israeli firm Oramed for China rights to an oral insulin capsule, paving the way for further changes in the country’s huge diabetes market. Hefei meanwhile is pushing ahead with plans to become China’s high-end insulin production base, helped by several cross-border collaborations.
Register for our free email digests: